Hybrid closed-loop artificial pancreas system improves blood sugar control better than insulin injections in hospitalized type 1 diabetes
Key takeaway:
A 28-year-old woman with long-standing type 1 diabetes had better blood sugar control and fewer low blood sugar episodes when using a hybrid closed-loop artificial pancreas system compared to multiple insulin injections during a hospital stay.
Study at a glance
What was studied
Hybrid closed-loop artificial pancreas versus multiple insulin injections in hospitalized type 1 diabetes
Study type
non-randomized clinical trial (non-RCT or NRCT)
duration
Short-Term (≤3 mo)
Intervention
Hybrid closed-loop system
Outcomes
Time in range, Time below range, Blood glucose, Time above range, Hypoglycemia events, Glucose variability
Funding
Non-industry sponsored
Main effects
↑ Time in target range (3.9-10 mmol/L): increased from 65% to 87%
↓ Severe hypoglycemia: reduced from 1.8% to 0.4% of time
↓ Mean blood glucose: decreased from 8.03 to 6.93 mmol/L
Evidence Suggest
- HCL system significantly increased time in range compared to multiple daily injections (87% vs 65%, p<0.05)
- Automated insulin delivery reduced severe low blood sugar events (glucose <3.0 mmol/L) by 78%
- Blood sugar fluctuations were smoother throughout the day and night, especially after meals and during sleep
Who this applies to
This case involved a 28-year-old woman with long-standing type 1 diabetes (17 years), elevated HbA1c (11.9%), history of poor glucose control, and frequent hypoglycemia. The findings may be most relevant for adults with type 1 diabetes who have difficulty achieving stable glucose control with insulin injections, particularly those experiencing frequent low blood sugar episodes.
Keep in Mind
This is a single case report, not a controlled study with multiple participants, so the results should be interpreted cautiously. The patient was hospitalized and closely monitored, which may not reflect typical outpatient care. The Android-based hybrid closed-loop system used is a do-it-yourself (DIY) system that is not commercially approved or regulated in China, and requires significant technical knowledge to set up and maintain. The cost of insulin pumps and CGM devices is not covered by medical insurance in China, limiting accessibility for most patients.
Between the Lines
- Case report of only one patient - results may not apply to all people with type 1 diabetes
- Short observation period of just 7 days for each treatment method
- Patient was hospitalized, so results may differ in outpatient or real-world settings
- AndroidAPS system is not commercially approved in China and requires technical expertise to set up
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Journal Reference
Li S, Lv P, Lu H, et al. Initiation of Hybrid Closed-Loop Artificial Pancreas System Improves Glycemic Control in a Hospitalized Type 1 Diabetes: A Case Report and Review. Case Rep Endocrinol. 2026;2026:8925266. doi:10.1155/crie/8925266
Sources
Ranked by clinical relevance and evidence quality.
Key References
Most relevant evidence and guidance related to this research.
ADA/EASD Consensus Report: The Management of Type 1 Diabetes in Adults
Supporting Evidence
Supporting evidence and related resources.
Overview | MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes | Advice | NICE
CGM & Time in Range | American Diabetes Association
Driver's License Information | ADA
Best Protein-Rich Foods for Diabetes | American Diabetes Association
NIDDK: Continuous Glucose Monitoring
Glycaemic Outcomes of a Novel Model-Predictive-Control-Based Hybrid Closed-Loop System in Chinese Adolescents and Adults With Type 1 Diabetes: A Multicentre Pivotal Trial.
13 total sources in this category
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.